Literature DB >> 2244853

Whole blood impedance platelet aggregometry and ischemic heart disease. The Caerphilly Collaborative Heart Disease Study.

P C Elwood1, A D Beswick, D S Sharp, J W Yarnell, S Rogers, S Renaud.   

Abstract

The Caerphilly Collaborative Heart Disease Study is based on a large cohort of men who were ages 49 to 64 years at the time of the study. We report the results for platelet aggregation measured in whole blood from a subsample of 308 men. The index of sensitivity used was the minimum concentration of adenosine diphosphate that produced a defined degree of impedance change in the Chronolog 560 aggregometer. There was a marked association between aggregation and prevalent ischemic heart disease (IHD). The odds ratios and 95% confidence intervals (CI) for prevalent IHD in men with the most sensitive platelets compared with those with the least sensitive platelets were 3.6 (95% Cl: 1.1 to 12.2) for angina; 7.3 (95% Cl: 2.0 to 24.3) for previous myocardial infarction (MI); and 2.7 (95% Cl: 1.0 to 7.6) for electrocardiogram evidence of ischemia. The confidence limits for these odds ratios are large because of the small sample size, but the estimates of odds ratio are relatively large compared to similar relationships between the traditional risk factors of serum cholesterol, blood pressure, smoking, and prevalent IHD (1.5 to 2.5). A number of factors that might confound the relationships between platelets and IHD were examined, but the associations remained statistically significant when these were taken into account.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2244853     DOI: 10.1161/01.atv.10.6.1032

Source DB:  PubMed          Journal:  Arteriosclerosis        ISSN: 0276-5047


  7 in total

1.  Platelet aggregation and incident ischaemic heart disease in the Caerphilly cohort.

Authors:  P C Elwood; S Renaud; A D Beswick; J R O'Brien; P M Sweetnam
Journal:  Heart       Date:  1998-12       Impact factor: 5.994

Review 2.  Regulation of platelet function by class B scavenger receptors in hyperlipidemia.

Authors:  Alejandro Zimman; Eugene A Podrez
Journal:  Arterioscler Thromb Vasc Biol       Date:  2010-11-11       Impact factor: 8.311

3.  Temperature and risk factors for ischaemic heart disease in the Caerphilly prospective study.

Authors:  P C Elwood; A Beswick; J R O'Brien; S Renaud; R Fifield; E S Limb; D Bainton
Journal:  Br Heart J       Date:  1993-12

4.  Replication and hematological characterization of human platelet reactivity genetic associations in men from the Caerphilly Prospective Study (CaPS).

Authors:  John D Eicher; Luting Xue; Yoav Ben-Shlomo; Andrew D Beswick; Andrew D Johnson
Journal:  J Thromb Thrombolysis       Date:  2016-02       Impact factor: 2.300

5.  Platelet function and myocardial injury during percutaneous coronary intervention.

Authors:  Nawsad Saleh; Lars-Olof Hansson; Maria Kohut; Tage Nilsson; Per Tornvall
Journal:  J Thromb Thrombolysis       Date:  2002-04       Impact factor: 2.300

6.  Population pharmacodynamic modelling of aspirin- and Ibuprofen-induced inhibition of platelet aggregation in healthy subjects.

Authors:  Ying Hong; Fran M Gengo; Michelle M Rainka; Vernice E Bates; Donald E Mager
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

Review 7.  Role of Gut Microbiota and Their Metabolites on Atherosclerosis, Hypertension and Human Blood Platelet Function: A Review.

Authors:  Asim K Duttaroy
Journal:  Nutrients       Date:  2021-01-03       Impact factor: 5.717

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.